אליסיו תונפק בכ-450 מ ד ; כלל ביו בפרטים חדשים על הספאק bizportal.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizportal.co.il Daily Mail and Mail on Sunday newspapers.
ישראל ביוטק פאנד השלימה גיוס של 112 מיליון דולר לקרן השנייה שלה themarker.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarker.com Daily Mail and Mail on Sunday newspapers.
Illustrative: A cancer patient and a perfusion drip. (CIPhotos, iStock by Getty Images)
Israeli cancer immunotherapy firm startup Biond Biologics said Tuesday it has entered an exclusive worldwide license agreement with Paris-based multinational pharma firm Sanofi for the development and commercialization of its flagship anti-tumor drug BND-22.
Under the terms of the agreement, Biond will get an upfront payment of $125 million in cash and could get $1 billion once it meets development, regulatory and sales milestones, as well as tiered double-digit royalty payments, the Israeli firm said in a statement.
Biond will lead the first-in-human, phase 1a study of BND-22, evaluating its safety and tolerability as a single drug and also in combination with approved cancer therapeutics. The firm will also explore potential associations between the anti-tumor activity of BND-22 and select tumor and blood-based biomarkers.
Share this article
MISGAV, Israel, Jan. 12, 2021 /PRNewswire/
Biond Biologics Ltd. ( Biond or the Company ), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced that it has entered into an exclusive worldwide license agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY), for the development and commercialization of BND-22.
BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors. ILT2, a member of the ILT family of immuno-modulating receptors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds MHC class I molecules including HLA-G, an immunosuppressive protein expressed by multiple tumor types.
1 $Milliard! Biond Biologics Ltd (Israël) et Sanofi (France) signent un accord géant israelvalley.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from israelvalley.com Daily Mail and Mail on Sunday newspapers.